LONDON & BOSTON--(BUSINESS WIRE)--Synthace, the first life sciences software company to enable scientists to automate biology experimentation and insight sharing in a unified, global R&D environment today announced it raised $35 million in Series C funding. This is exactly why Synthace recently released the first life sciences R&D cloud, a no-code software platform that addresses simplification, speed, and reproducibility for scientists thereby removing barriers to innovation. Business highlights include: • Achieved more than 225% increase in annual recurring revenue • Signed 5 new, strategic GTM partnerships with R&D lab equipment suppliers (Tecan, SPT Labtech, Repligen, Hamilton, and BioTek) “Biopharmaceuticals are in the global spotlight like never before. And with an industry calling out for advanced R&D technologies to help keep it innovating at pace, Synthace is meeting the challenge by enabling customers to accelerate their R&D practices,” said Patrick Zhang, investor at Horizons Ventures. Top global pharmaceuticals, high-growth biotech companies, leading CDMOs, and innovators in artificial intelligence all turn to Synthace to discover solutions to humanity’s hardest problems.